These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23576131)

  • 1. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence.
    Ravenni R; De Grandis D; Mazza A
    Neurol Sci; 2013 Jul; 34(7):1043-8. PubMed ID: 23576131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
    Scaglione F
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
    Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
    Hubble J; Schwab J; Hubert C; Abbott CC
    Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
    Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
    Eur J Neurol; 2009 Mar; 16(3):392-8. PubMed ID: 19364366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine use of Xeomin in patients previously treated with Botox: long term results.
    Dressler D
    Eur J Neurol; 2009 Dec; 16 Suppl 2():2-5. PubMed ID: 20002739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
    Frevert J
    Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective evaluation of the dose equivalence of Botox(®) and Dysport (®) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story.
    Bentivoglio AR; Ialongo T; Bove F; De Nigris F; Fasano A
    Neurol Sci; 2012 Apr; 33(2):261-7. PubMed ID: 21710123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
    Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC
    Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
    Ranoux D; Gury C; Fondarai J; Mas JL; Zuber M
    J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):459-62. PubMed ID: 11909903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport.
    Kollewe K; Mohammadi B; Dengler R; Dressler D
    J Neural Transm (Vienna); 2010 Jun; 117(6):759-63. PubMed ID: 20437061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
    Rystedt A; Zetterberg L; Burman J; Nyholm D; Johansson A
    Clin Neuropharmacol; 2015; 38(5):170-6. PubMed ID: 26366966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.
    Odergren T; Hjaltason H; Kaakkola S; Solders G; Hanko J; Fehling C; Marttila RJ; Lundh H; Gedin S; Westergren I; Richardson A; Dott C; Cohen H
    J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):6-12. PubMed ID: 9436720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin A (Dysport®): in dystonias and focal spasticity.
    Keam SJ; Muir VJ; Deeks ED
    Drugs; 2011 May; 71(8):1043-58. PubMed ID: 21668041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.